- Edgewise to advance heart drug into Phase 3 following mid-stage data updateEdgewise Therapeutics has shared plans to advance its drug candidate for a genetic heart disease into a registrational study on the back of updated Phase 2 data. The biotech said Tuesday ...Endpoints · 1mo ago↗ source
- How to launch a telehealth business in one dayWant to prescribe GLP-1s online? OpenLoop Health says it can get your virtual care company up and running in as little as 24 hours. OpenLoop provides the behind-the-scenes medical group powering…Endpoints · 1mo ago↗ source
- Lilly buys another pain biotech; FDA sets decision for once-weekly PrEP pillPlus, news about Merck, MultiValent Biotherapies, Alvotech, enGene, Mirum, and Adaptive Biotechnologies. 💸 Eli Lilly acquires another pain biotech: The Indianapolis pharma giant has made its 11t…